Abstract
Mycobacterium tuberculosis (the causative agent of tuberculosis), is a stealthy pathogen with a great ability to successfully infect humans and a strong will to stay in the host as long as possible. As much as one admires it as a microbiological entity, M. tuberculosis is also a killer at large responsible for an annual death toll of more than two million people worldwide. Treatment of tuberculosis is a lengthy process that requires multiple drugs for at least six months and although a worldwide health policies established by World Health Organization (WHO) helped reducing the rate of treatment failure, the appearance of novel forms of drug- resistant M. tuberculosis has become a major issue during the last years. The advances in the knowledge of the genetics of this pathogen have allowed for a better understanding of its physiology which in turn helped unveiling the mechanisms of drug action and the ensuing mechanisms of resistance. Surprisingly, it was found that most of the specific anti-tubercular drugs target the synthesis of mycolic acids, long chain fatty acids that are essential components of the cell wall structure. This review highlights the studies on anti-tubercular agents that abrogate the synthesis of mycolic acids with special emphasis on molecules that might be added to the therapeutic weaponry to treat tuberculosis.
Keywords: Tuberculosis, mycolic acid biosynthesis, enoyl-ACP reductase, isoniazid, ethionamide, isoxyl, thiacetazone
Current Respiratory Medicine Reviews
Title: Bringing Down the Wall of the Mycobacterium tuberculosis Fortress: Old and New Inhibitors of Mycolic Acid Biosynthesis
Volume: 5 Issue: 3
Author(s): Hector R.. Morbidoni
Affiliation:
Keywords: Tuberculosis, mycolic acid biosynthesis, enoyl-ACP reductase, isoniazid, ethionamide, isoxyl, thiacetazone
Abstract: Mycobacterium tuberculosis (the causative agent of tuberculosis), is a stealthy pathogen with a great ability to successfully infect humans and a strong will to stay in the host as long as possible. As much as one admires it as a microbiological entity, M. tuberculosis is also a killer at large responsible for an annual death toll of more than two million people worldwide. Treatment of tuberculosis is a lengthy process that requires multiple drugs for at least six months and although a worldwide health policies established by World Health Organization (WHO) helped reducing the rate of treatment failure, the appearance of novel forms of drug- resistant M. tuberculosis has become a major issue during the last years. The advances in the knowledge of the genetics of this pathogen have allowed for a better understanding of its physiology which in turn helped unveiling the mechanisms of drug action and the ensuing mechanisms of resistance. Surprisingly, it was found that most of the specific anti-tubercular drugs target the synthesis of mycolic acids, long chain fatty acids that are essential components of the cell wall structure. This review highlights the studies on anti-tubercular agents that abrogate the synthesis of mycolic acids with special emphasis on molecules that might be added to the therapeutic weaponry to treat tuberculosis.
Export Options
About this article
Cite this article as:
Morbidoni R.. Hector, Bringing Down the Wall of the Mycobacterium tuberculosis Fortress: Old and New Inhibitors of Mycolic Acid Biosynthesis, Current Respiratory Medicine Reviews 2009; 5 (3) . https://dx.doi.org/10.2174/157339809788922397
DOI https://dx.doi.org/10.2174/157339809788922397 |
Print ISSN 1573-398X |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6387 |
Call for Papers in Thematic Issues
Exposure to PM2.5 components is associated with respiratory diseases
Through continuous research on the relationship between risk factors and health, it has been found that air pollution, especially atmospheric particulate matter pollution, has become one of the main sources of global disease burden. From 1990 to 2022, the concentration of atmospheric particulate matter pollution has increased by more than ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Advancements within Modern Machine Learning Methodology: Impacts and Prospects in Biomarker Discovery
Current Medicinal Chemistry Adjunctive Immunotherapeutic Efficacy of N-Formylated Internal Peptide of Mycobacterial Glutamine Synthetase in Mouse Model of Tuberculosis
Protein & Peptide Letters Quickness of HIV and Tuberculosis Diagnostic Procedures in Prison of Tehran, Iran
Infectious Disorders - Drug Targets 3,4-Dihydropyrimidin-2(1H)-One Analogues: Microwave irradiated Synthesis with Antimicrobial and Antituberculosis Study
Current Microwave Chemistry Fused Aryl-Phenazines: Scaffold for the Development of Bioactive Molecules
Current Drug Targets Current Understanding of Interactions between Nanoparticles and ABC Transporters in Cancer Cells
Current Medicinal Chemistry Iron Regulation in Tuberculosis Research: Promise and Challenges
Current Medicinal Chemistry Integration of Biological Data with Semantic Networks
Current Bioinformatics IL-1 as a target in inflammation
Endocrine, Metabolic & Immune Disorders - Drug Targets The Need to Teach Vaccine Safety to Basic Scientists and Public Health Officials
Current Drug Safety The Chemical Dynamics of NO and Reactive Nitrogen Oxides: A Practical Guide
Current Molecular Medicine Stairway to Heaven or Hell? Perspectives and Limitations of Chagas Disease Chemotherapy
Current Topics in Medicinal Chemistry Mode of Action of Anti-Infective Agents Focus on Oxidative Stress and Electron Transfer
Current Pharmaceutical Design Targeted Drug Delivery Using Tuftsin-bearing Liposomes: Implications in the Treatment of Infectious Diseases and Tumors
Current Drug Targets Synthesis and Antimycobacterial Activity of 3-(Arylaminomethyl)-5- (Pyridin-4-yl)-1,3,4-Oxadiazole-(3H)-thi-2-One Derivatives Against <i>Mycobacterium Tuberculosis</i> H37rv Strain
Current Bioactive Compounds Safety and Efficacy of Thioridazine as Salvage Therapy in Indian Patients with XDR-TB
Recent Patents on Anti-Infective Drug Discovery Quinoline-3-carboxylate Derivatives: A New Hope as an Antiproliferative Agent
Anti-Cancer Agents in Medicinal Chemistry Gauging Reactive Metabolites in Drug-Induced Toxicity
Current Medicinal Chemistry Synthesis and Biological Evaluation of Novel N' (4-aryloxybenzylidene)- 1H-Benzimidazole-2 Carbohydrazide Derivatives as Anti-Tubercular Agents
Combinatorial Chemistry & High Throughput Screening A Computational Molecular Docking Studies on the Tryparedoxin Peroxidase of <i>Leishmania donovani</i> Responsible for Visceral Leishmaniasis in Human
Letters in Drug Design & Discovery